8-K: Evolus Achieves Record Revenue in 2024, Projects Continued Growth and Profitability in 2025

Evolus reports record preliminary unaudited net revenue for 2024, exceeding guidance and projecting continued growth and profitability in 2025 with the upcoming launch of new products.

Summary

• Evolus announced preliminary unaudited net revenue of $79.0 million for the fourth quarter of 2024, a 30% increase year-over-year.
• Full-year 2024 net revenue reached $266.3 million, a 32% increase over 2023, and at the top of the company's guidance.
• The company added over 2,900 new accounts in 2024, bringing the total to over 15,300, surpassing 50% account penetration in the U.S.
• Evolus expects FDA approval for Evolysse injectable HA gels within 90 days, with a U.S. launch planned for Q2 2025, ahead of the prior timeline.
• 2025 net revenue is projected to be between $345 million and $355 million, representing 30% to 33% growth from 2024.
• Evolysse and Estyme injectable HA gels are expected to contribute 8-10% of total revenue in 2025.
• Non-GAAP operating expenses for 2025 are estimated to be between $230 million and $240 million.
• Evolus anticipates achieving positive non-GAAP operating income for the full-year 2025, concentrated in Q4.

Sentiment

Score: 8

Explanation: The document conveys a very positive outlook with strong revenue growth, new product launches, and a clear path to profitability. The company is exceeding expectations and has a strong growth trajectory.

Positives

• Evolus exceeded 30% revenue growth for the fifth consecutive year.
• The company's reorder rate among customers remains strong at approximately 70%.
• Enrollment in the Evolus Rewards consumer loyalty program grew over 40% in 2024, reaching approximately 1.1 million consumers.
• Evolus had $87.0 million in cash and cash equivalents as of December 31, 2024, up from $85.0 million on September 30, 2024.
• The company is transitioning from a single-product company to a multi-product innovator with the upcoming launch of Evolysse.

Negatives

• The preliminary results are unaudited and subject to change until the audit of the company's 2024 financial results is completed.
• Non-GAAP operating income is anticipated to be concentrated in Q4 2025, with investments ramping up in Q1.

Risks

• The company's ability to comply with the terms and conditions in the Medytox Settlement Agreements is a risk.
• Unfavorable global economic conditions could impact consumer discretionary spending and affect the company's performance.
• There are uncertainties related to customer and consumer adoption of Jeuveau and Evolysse.
• The company's ability to successfully launch and commercialize products in new markets, including Evolysse HA gels in the U.S., is a risk.
• The company relies on Symatese to achieve regulatory approval for the Evolysse HA gel line in the U.S.

Future Outlook

Evolus projects continued revenue growth of 30% to 33% in 2025, with the launch of new products contributing to this growth. The company expects to achieve positive non-GAAP operating income for the full-year 2025 and aims to reach at least $700 million in net revenue and a non-GAAP operating income margin of at least 20% by 2028.

Management Comments

• David Moatazedi, President and CEO, stated that the preliminary results underscore the strength of their operational execution and significant market share gains.
• Moatazedi highlighted that the company exceeded 30% revenue growth for the fifth consecutive year, delivering results at multiples above the market.
• Moatazedi mentioned that the U.S. filing for Evolysse is ahead of schedule and they expect to receive FDA approval within the next 90 days.
• Moatazedi noted that next quarter, they will transition from a single product company to a multi-product innovator.

Industry Context

Evolus is operating in the competitive aesthetics market, focusing on neurotoxins and hyaluronic acid fillers. The company's growth is driven by increased market share and expansion into new product categories. The launch of Evolysse is a key step in diversifying their product portfolio and competing with established players in the HA filler market.

Comparison to Industry Standards

• Evolus's 32% revenue growth in 2024 significantly exceeds the average growth rate in the aesthetics market, which is typically in the high single digits to low double digits.
• Companies like Allergan (now part of AbbVie) and Galderma are major competitors in the neurotoxin and HA filler markets, and Evolus is aiming to gain market share through its differentiated products and business model.
• The company's focus on a cash-pay model and digital platform is a unique approach compared to some traditional players in the industry.
• Evolus's goal of achieving a 20% non-GAAP operating income margin by 2028 is ambitious and would place them among the more profitable companies in the aesthetics sector.

Stakeholder Impact

• Shareholders are likely to react positively to the strong revenue growth and positive outlook.
• Employees may be motivated by the company's success and growth prospects.
• Customers will have access to new products with the launch of Evolysse.
• Suppliers may benefit from increased demand for Evolus's products.

Next Steps

• Evolus expects to receive FDA approval for Evolysse injectable HA gels within the next 90 days.
• The company plans to launch Evolysse in the U.S. in Q2 2025.
• Evolus will report its full financial results for Q4 and full-year 2024 in early March 2025.

Key Dates

Keywords

Evolus, Jeuveau, Nuceiva, Evolysse, Estyme, Neurotoxin, Hyaluronic Acid, Aesthetics, Revenue, Profitability, FDA Approval, Non-GAAP Operating Income